https://www.facebook.com/104204448655986/

GP and women's health professionals study day, UCLH, London (2026)

22/01/2026

Thank you Ieera Madan Aggarwal, Gayathri Delanerolle and the MARIE Consortium for this qualitative study which formed part of the multi-country MARIE project on menopause and midlife health.

Eighteen participants from Singapore at different menopausal stages were purposively sampled ensuring variation in age, ethnicity, socio-economic status and health status. Semi-structured interviews explored symptom profiles, psychosocial well-being, family and workplace dynamics, and healthcare experiences. Data were analysed using the Delanerolle and Phiri framework, integrating biological, psychological, sociocultural and health system domains.��What did we find?
Participants described heterogeneous symptom trajectories, with vasomotor, genitourinary and cognitive symptoms as most prominent. Multimorbidity and surgical menopause intensified symptom burden and narrowed treatment options. Anxiety, low mood and brain fog impaired work, particularly without workplace support. Sociocultural silences and misinformation reinforced self-management and delayed care-seeking. Resilience rooted in peer and family support, and culturally familiar coping strategies buffered distress for some.
Health system gaps included inconsistent general practitioner's knowledge, reluctance to prescribe hormone therapy and private care costs. Study participation itself triggered symptom recognition and help-seeking in some, underscoring menopause invisibility in routine care.�
Findings highlight that menopause in Singapore is navigated through intersecting clinical, cultural and structural determinants. Addressing inequities requires embedding women’s voices into clinical pathways, training clinicians in culturally competent care, and implementing workplace and public health policies that legitimise menopause as a health and occupational issue.

https://annals.edu.sg/navigating-menopause-in-singapore-sociocultural-clinical-and-policy-implications-from-a-qualitative-study-marie-singapore/

21/01/2026

Thank you Dani Binnington and team at Menopause and Cancer CIC for this opportunity and responsibility.
Hopefully we can continue to work harder together to improve menopause experiences for cancer survivors not just in the UK but across the globe.
https://menopauseandcancer.org

18/01/2026

Thank you Nigel Denby and team at YOUR MENOPAUSE by Harley Street at Home for the opportunity to join ‘Clinical Conundrums’ session on coming Tuesday 20th January.

It will be an opportunity to discuss complex menopause cases (theme of the session - Menopause for Women with Pre Existing Health Conditions) and address practical clinical questions for all of us.

Looking forward to the session.
https://your-menopause-by-harley-street-at-home.circle.so/c/clinical-conundrums?post_login_redirect=https%3A%2F%2Fyour-menopause-by-harley-street-at-home.circle.so%2Fc%2Fclinical-conundrums%2Fmenopause-for-women-with-pre-existing-medical-conditions

17/01/2026

Looking forward to discussing some of the new papers/studies in the world of menopause and post-reproductive health with Fiona Clark on Monday.

Do join us on this learning journey with the Menopause Research and Education Fund (MREF).

We will aim to cover HRT after BRCA diagnosis; GSM, UTIs and vaginal oestrogen; Vaginal oestrogen and re**al cancer; Meningioma and HRT; Aging and HRT and Testosterone in menopause - the recent North American society guidelines.

Every piece of research matters - the aim is to understand the strengths and weaknesses of these studies/recommendations and how to make their best use in clinical practice.

Join us live on Monday 19th January at 6:45 pm or watch later on YouTube MREF channel.

16/01/2026

Some food for thought and future research -

Phosphodiesterase type 5 inhibitors (PDE5 inhibitors) share common characteristics and a similar mode of action. These medications work by blocking the action of the enzyme PDE5, which is responsible for breaking down cyclic GMP (cGMP) in the smooth muscle cells lining the blood vessels. By inhibiting PDE5, these drugs promote the accumulation of cGMP, leading to vasodilation in the smooth muscle cells of the blood vessels.
Initially developed as a potential intervention for cardiovascular disease, the drugs including sildenafil (Vi**ra) are today used for treatment of erectile dysfunction and pulmonary hypertension.

But can they have another role for women in menopause transition and beyond? We know that there is a lack of good quality female-specific research and preventative interventions when it comes to cardiovascular health in women and there is a need to develop this space more with better research into both lifestyle and medical treatments including hormonal (HRT) and non-hormonal strategies.

Here is a take on PDE5 inhibitors and their potential. A rationale for PDE5 inhibitors as a cardiovascular risk mitigation strategy in postmenopausal women. doi: https://doi.org/10.1093/jsxmed/qdaf397

15/01/2026

This RCOG guideline provides comprehensive information on risk factors, recommended investigations and treatments for recurrent first trimester and one or more second trimester miscarriages.

It also discusses provisions for the management of any subsequent miscarriages, in terms of women and people receiving appropriate supportive care via informed communication with healthcare professionals, ultrasound examinations and prompt access to services.https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/recurrent-miscarriage-green-top-guideline-no-17/

14/01/2026

Menopause transition will potentially affect 50% or more of the population, however education on this topic for undergraduate medical students appears to be limited. We are conducting a short survey to gain better understanding of the extent of menopause education in medical schools in the UK so that we can use this information to advocate for a change in the current curriculum as needed.
Thank you Riya Philip from the University of Glasgow for taking this forward.
If you are able to participate, please click - https://forms.gle/J4BBPesijGX7g7SX6 or scan the QR code
or share with someone who may be interested.

13/01/2026

On behalf of Reproduction and Fertility, I invite you to contribute to the recently launched collection “Evolving Perspectives in Management of Menopause Transition”. The collection is being led by myself as Collection Editor alongside Hisham AlAhwany.

Reproduction and Fertility has a global readership and an Impact Factor of 3.4 (Q1 journal).
Co-Editors in Chief -
Andrew Horne, PhD FRCOG FRCP Edin FRCSEd FRSE
Professor of Gynaecology and Reproductive
Sciences,
MRC Centre for Reproductive Health,
University of Edinburgh, UK
and
Norah Spears, D Phil
Professor of Reproductive Physiology,
Centre for Integrative Physiology,
University of Edinburgh, UK

Key areas we will aim to cover -
* Management of menopause symptoms with non-hormonal therapies and the advent of novel therapies like NK-3 receptor antagonists
* Hormone replacement therapy for menopause - where are we now?
* Cardiovascular and bone health in menopause
* Premature ovarian insufficiency and early menopause
* Menopause and Cognitive health
* Testosterone therapy during menopause
* Managing menopause after cancer - what do we know and how is it different?
* Addressing global inequalities in menopause care and support - how do we overcome barriers and challenges that lie ahead?

You can find out more about article submission at -
raf@bioscientifica.com

Or click

https://raf.bioscientifica.com/page/menopause-transition/evolving-perspectives-in-management-of-menopause-transition-

11/01/2026

A big thank you to all staff and colleagues at London Medical (49 Marylebone High Street) for all the help and support over the past 6 years. Forever grateful to the admin team - Soga Matthew, Sahra Munye and Ruzi Hamid and all the healthcare assistants for the wonderful support with reproductive endocrine and menopause clinics 🙏🏼.
And finally not to forget all the patients who have been an amazing source of learning in this journey. - thank you!

Here are some of the free patient information resources we created at London Medical -

https://londonmedical.co.uk/gp-services/menopause-and-hormone-replacement-therapy-hrt/

https://londonmedical.co.uk/news-and-events/recurrent-miscarriage-questions/

https://londonmedical.co.uk/news-and-events/what-is-pcos/

10/01/2026

Vaginal oestrogens (pessaries, gel, cream or ring) are a safe and effective treatment for genitourinary symptoms (dryness, pain, irritation, bladder issues, UTIs) of menopause (GSM). There is minimal (clinically non-significant) systemic absorption of oestrogen from low dose vaginal products.
Although basic principles of management of GSM in breast cancer survivors remain similar, there are some differences in how various guidelines approach or recommend the use of different non-hormonal and hormonal preparations based on the type of cancer.

Some guidelines including the British Menopause Society recommend vaginal moisturisers and lubricants as the first-line treatment for GSM following breast cancer. The guidelines recommend that low-dose vaginal oestrogen can be considered in women who have oestrogen receptor negative tumours or who are taking tamoxifen and have not found non-hormonal treatments effective for GSM. Oestrogen therapy should be discussed with the woman’s oncology team. Low-dose vaginal oestrogens are not recommended for women taking aromatase inhibitors although not absolutely contraindicated. Guidelines emphasise the need for collaborative decision making, including the
patient’s breast oncology team, if non-hormonal treatments are unsuccessful and vaginal oestrogen therapy is being considered.
In most guidelines, medications for GSM such as the oral Ospemifene (Selective Estrogen Receptor Modulator) and vaginal dehydroepiandrosterone (DHEA) are currently not recommended for this group of women as there is a lack of evidence about long-term safety. Recent BMS guidance on GSM suggests that Ospemifene can
be offered to women with a history of breast and endometrial cancer, who have completed
treatment.

The American College of Obstetricians and Gynecologists also recommends non-hormonal methods as the first-line treatment. These include silicone-, polycarbophil-, and water-based lubricants, hyaluronic acid, polyacrylic acid, and vitamin E and D vaginal suppositories. It advises that when non-hormonal treatments fail to address symptoms, low-dose vaginal oestrogen may be used as the next treatment option including for those individuals who take tamoxifen. For individuals taking aromatase inhibitors, ACOG suggests that low-dose vaginal oestrogen can be used after shared decision making between the patient, Gynaecologist, and Oncologist. The guidelines go on to advise that if vaginal oestrogen is not an option, vaginal DHEA or testosterone may help with painful s*x and improve vaginal tissue health and that oral Ospemifene may be considered yet another treatment option.

Decision making can be tricky for patients and they need as much information as possible to make an informed choice. There is also a need for good quality RCTs on this topic. We summarise the evidence and talk about the decision making process in Dani Binnington’s book on ‘Navigating Menopause After Cancer’.

https://menopauseandcancer.org/book/

https://thebms.org.uk/wp-content/uploads/2025/11/09-NEW-BMS-ConsensusStatement-Genitourinary-Syndrome-of-Menopause-GSM-NOV2025-B.pdf

https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2021/12/treatment-of-urogenital-symptoms-in-individuals-with-a-history-of-estrogen-dependent-breast-cancer

https://thebms.org.uk/publications/consensus-statements/risks-and-benefits-of-hrt-before-and-after-a-breast-cancer-diagnosis/

https://journals.sagepub.com/doi/10.1177/20533691231208473?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

09/01/2026

Join us for a case based discussion on menopause transition and HRT. Thank you Assimilate for the opportunity 🙏🏼.

🗓 January 12th Monday
⏰ 𝟏𝟏:𝟎𝟎 𝐀𝐌 – 𝟏𝟐:𝟎𝟎 𝐏𝐌 (𝐔𝐊 𝐓𝐢𝐦𝐞)
⏰ 𝟒:𝟑𝟎 𝐏𝐌 – 𝟓:𝟑𝟎 𝐏𝐌 (𝐈𝐒𝐓)

https://assimilate.one/case-discussion/menopause-transition-and-hormone-replacement-therapy/

07/01/2026

Learn and connect: menopause and cardiovascular health

Menopause transition is associated with several hormone changes that impact long-term health including cardiovascular function. Since the publication of landmark studies such as the WHI and the Million Women's study, we have learned so much regarding the benefits and risks of modern hormone replacement therapy that is highly relevant to all physicians who care for women at risk for or those with established cardiovascular disease (CVD).

This meeting will focus on the cardiovascular changes during menopause and the management (lifestyle, hormonal and non-hormonal) of symptomatic women, including those with risk factors for CVD as well as those with stable CVD.

Join us for this exciting RCGP session at 30 Euston Square, London chaired by North and West London Faculty's Dr Alba Soares-Pereira.

Register at RCGP website (search in events) or
https://royalcollegeofgeneralpractitioners.my.site.com/event/a2kWS000000TUbN/ev05943?recordId=a2kWS000000TUbN&utm_campaign=3012298_London%20%26%20South%20England%20Faculty%20Fortnightly%206%20January&utm_medium=email&utm_source=Dotmailer&dm_i=49LX,1SKAY,JUZQT,8H927,1

GP and women's health professionals study day

22/01/2026

21/01/2026

18/01/2026

17/01/2026

16/01/2026

15/01/2026

14/01/2026

13/01/2026

11/01/2026

10/01/2026

09/01/2026

07/01/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share

Category